-
(单词翻译:双击或拖选)
U.S. pharmaceutical1 giant Merck announced on Monday that it plans to acquire rival company Schering-Plough in a deal worth $41.1 billion. This could help Merck expand its market overseas at a critical time for mega pharmaceutical companies.
Merck & Co. headquarters is seen in Whitehouse Station, New Jersey2 (File)
The New Jersey-based drug companies announced they will combine under Merck's name in a deal financed through cash and stock. Under the agreement, Schering-Plough shareholders3 will receive $10.50 in cash and a little more than half a Merck share for each of their existing shares.
Merck Chief Executive Officer Richard Clark, who will lead the new company, says shareholders will benefit from its more efficient operating structure and expanded research.
"The combined strength of Merck and Schering-Plough will create a company that can deliver consistent, sustainable growth and meaningful value for shareholders," he said.
The merger4 comes six weeks after Pfizer, the world's largest drug maker5, acquired rival Wyeth for $68 billion. Both Merck and Pfizer are facing the expiration6 of patents on several of their best-selling drugs and seek to diversify7 their portfolios8.
Schering-Plough generates 70 percent of its sales outside of the United States, including more than $2 billion a year from emerging markets. Clark says the merger will accelerate Merck's effort to develop its presence abroad. With the merger, Clark says more than 50 percent of their combined revenue will be generated overseas.
Chairman of Schering-Plough, Fred Hassan, says the merger will help both companies during the economic downturn.
"The stunning9 and accelerating changes in the global macro environment are driving stunning and accelerating changes in our own industry's environment," he said. "Our board concluded that this was the right transaction at the right time."
Yet analysts10 say the Merk and Pfizer mergers11 may signal a broader shift among pharmaceutical companies to protect themselves from a harsher economic climate and the increasing competitiveness of generic12 drugs.
Professor at the University of North Carolina Pharmacy13 School Fred Eckel says while Merck will reduce its overall cost of operation, it does not mean it will instantly come out with new top-selling drugs to replace its old ones.
"If you look at the number of new drug entities14 put on the market, there's been a significant decline in the last 10 years," he said. "And clearly the so-called blockbuster drugs, those that have broad appeal to chronic15 diseases that affect many patients, have not been there."
Merck says it will eventually cut about 15 percent of its workforce16 and expects the merger will save it some $3.5 billion annually17 after 2011.
1 pharmaceutical | |
adj.药学的,药物的;药用的,药剂师的 | |
参考例句: |
|
|
2 jersey | |
n.运动衫 | |
参考例句: |
|
|
3 shareholders | |
n.股东( shareholder的名词复数 ) | |
参考例句: |
|
|
4 merger | |
n.企业合并,并吞 | |
参考例句: |
|
|
5 maker | |
n.制造者,制造商 | |
参考例句: |
|
|
6 expiration | |
n.终结,期满,呼气,呼出物 | |
参考例句: |
|
|
7 diversify | |
v.(使)不同,(使)变得多样化 | |
参考例句: |
|
|
8 portfolios | |
n.投资组合( portfolio的名词复数 );(保险)业务量;(公司或机构提供的)系列产品;纸夹 | |
参考例句: |
|
|
9 stunning | |
adj.极好的;使人晕倒的 | |
参考例句: |
|
|
10 analysts | |
分析家,化验员( analyst的名词复数 ) | |
参考例句: |
|
|
11 mergers | |
n.(两个公司的)合并( merger的名词复数 ) | |
参考例句: |
|
|
12 generic | |
adj.一般的,普通的,共有的 | |
参考例句: |
|
|
13 pharmacy | |
n.药房,药剂学,制药业,配药业,一批备用药品 | |
参考例句: |
|
|
14 entities | |
实体对像; 实体,独立存在体,实际存在物( entity的名词复数 ) | |
参考例句: |
|
|
15 chronic | |
adj.(疾病)长期未愈的,慢性的;极坏的 | |
参考例句: |
|
|
16 workforce | |
n.劳动大军,劳动力 | |
参考例句: |
|
|
17 annually | |
adv.一年一次,每年 | |
参考例句: |
|
|